Official US documents have disclosed that a popular anti-stroke medicine may have used fictitious data while concealing research on its fatal effects. In 2009, the acclaimed British medical journal, The Lancet, published a prime story on rivaroxaban, a blood thinner medicine, which showed that the treatment was safe and efficient. But recently, the same journal warned of defaults in the trial data and claimed to initiate an investigation over it.

Lancet opens probe into ‘unreliable’ anti-stroke medicine

detection-of-clinically-significant-prostate-cancer

Detection Of Clinically Significant Prostate Cancer, News on Detection Of Clinically Significant Prostate Cancer, stories on Detection Of Clinically Significant Prostate Cancer, articles on Detection Of Clinically Significant Prostate Cancer, Detection Of Clinically Significant Prostate Cancer stories at Wion, Detection Of Clinically Significant Prostate Cancer news, Detection Of Clinically Significant Prostate Cancer latest news

detection of-clinically-significant-prostate-cancer

Lancet opens probe into ‘unreliable’ anti-stroke medicine